Neovasc to Participate in Sidoti December Virtual Microcap Conference
December 01 2021 - 9:05AM
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”)
(NASDAQ, TSX: NVCN) today announced that its management team
will be participating in the Sidoti December Virtual Microcap
Conference to be held December 8-9, 2021. Fred Colen,
President and Chief Executive Officer, will give a presentation on
Wednesday, December 8 at 3:15 pm EST. A link to the live
webcast of the presentation will be available in the Investor
Relations section of the Neovasc website at
https://www.neovasc.com/investors/. The recording will be archived
for 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel,
and Europe. For more information, visit: www.neovasc.com.
About Sidoti & Company
For over two decades, Sidoti & Company
(http://www.sidoti.com) has been a premier provider of independent
securities research focused specifically on small and microcap
companies and the institutions that invest in their securities,
with most of its coverage in the $100 million-$5 billion market cap
range. The firm’s approach affords companies and institutional
clients a combination of high-quality research, a small- and
microcap-focused nationwide sales effort, broad access to corporate
management teams, and extensive trading support. Sidoti serves 500+
institutional clients in North America.
Contacts
ICR Westwicke
Investors:
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com
Media:
Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words “expect”, “anticipate”, “estimate”, “may”,
“will”, “should”, “intend,” “believe”, and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, expectations as to
the future growth of the Company, the expansion of its product
range and the growing cardiovascular marketplace. Forward-looking
statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical
trends, current conditions and expected future developments, as
well as other factors that the Company believes are appropriate in
the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the three and six months ended June 30,
2019 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company’s forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024